In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on United Therapeutics (NASDAQ: UTHR), with a price target of $160. The company’s shares closed yesterday at $113.81.
Singh observed:
“We believe the United Therapeutics (UTHR) oral treprostinil pulmonary arterial hypertension (PAH) medication Orenitram’s label-expansion Phase 3 FREEDOM-EV clinical trial may be on the verge of reading out. ClinicalTrials.gov web entry, the trial stopped recruitment of patients in a study readout planned for as early as July 2018. We believe there is a 70% probability of success for a positive FREEDOM-EV readout with a +10% stock move, while a negative outcome would precipitate a -25% stock move. The risk/reward is balanced, but a positive outcome should go some distance in lifting some of the negative sentiment around UTHR. We stay bullish.”
According to TipRanks.com, Singh is a 4-star analyst with an average return of 12.4% and a 46.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $146.
See today’s analyst top recommended stocks >>
Based on United Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $245 million. In comparison, last year the company had a GAAP net loss of $56 million.
Based on the recent corporate insider activity of 107 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
